| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 07/02/2013 | US8475766 Dual specificity antibodies and methods of making and using |
| 07/02/2013 | US8475765 Hydroxyalkyl starch derivatives |
| 07/02/2013 | US8474954 System and a method for pharmaceutical dosage preparation using jettable microemulsions |
| 07/02/2013 | CA2750209C Coated solid preparations of valproic acid |
| 07/02/2013 | CA2747838C Synthesis of polymer conjugates of indolocarbazole compounds |
| 07/02/2013 | CA2647893C Pharmaceutical composition comprising lipase inhibitor and lipophilic oil absorbent and oral formulation prepared therefrom |
| 07/02/2013 | CA2600969C Soft gelatin capsules containing cyclodextrin in the capusle shell |
| 07/02/2013 | CA2588293C Rasagiline orally disintegrating compositions |
| 07/02/2013 | CA2575933C Stabilised prostaglandin composition |
| 07/02/2013 | CA2563101C Inclusion complexes obtained using a supercritical co2 process and an interaction agent with the compound |
| 07/02/2013 | CA2533849C Aminated complex-type sugar chain derivatives and process for the production thereof |
| 07/02/2013 | CA2530736C Pharmaceutical compositions comprising ph-sensitive block copolymers and a hydrophobic drug |
| 07/02/2013 | CA2522890C Method for selective inhibition of human n-myc gene in n-myc expressing tumors through anti-sense and sense peptide nucleic acids |
| 07/02/2013 | CA2521379C Pharmaceutical formulations containing methylnaltrexone |
| 07/02/2013 | CA2519705C Antifungal nail coat and method of use |
| 07/02/2013 | CA2512144C Solid surface for biomolecule delivery and high-throughput assay |
| 07/02/2013 | CA2504582C Drug delivery device comprising a bilayered polymeric coating having an inhibitor of the mamalian target of rapamycin incorporated into the first polymeric coating layer |
| 07/02/2013 | CA2502025C Pharmaceutical compositions having a modified vehicle |
| 07/02/2013 | CA2445729C Use of metals to treat mucosal membranes |
| 06/27/2013 | WO2013096940A1 Double binding constructs |
| 06/27/2013 | WO2013096939A1 Selective binding compounds |
| 06/27/2013 | WO2013096349A1 Transparent microemulsions with a film-forming styling polymer and methods for making the same |
| 06/27/2013 | WO2013095905A1 Thyroid stimulating hormone compositions |
| 06/27/2013 | WO2013095320A1 Flurbiprofen formulations |
| 06/27/2013 | WO2013095319A2 Formulations of flurbiprofen and diacerein |
| 06/27/2013 | WO2013095318A2 Orally-disintegrating formulations of flurbiprofen |
| 06/27/2013 | WO2013095317A2 Pharmaceutical formulations of flurbiprofen and glucosamin |
| 06/27/2013 | WO2013095166A1 Antibiotic formulations |
| 06/27/2013 | WO2013095042A2 Granule containing imatinib mesylate, immediate release oral tablet composition containing same, and preparation method thereof |
| 06/27/2013 | WO2013094683A1 Composition for skin containing silicone base |
| 06/27/2013 | WO2013093823A2 Topical oil composition for the treatment of fungal infections |
| 06/27/2013 | WO2013093753A1 Ivabradine hydrochloride premix |
| 06/27/2013 | WO2013093659A1 Natural, multiple release and re-use compositions |
| 06/27/2013 | WO2013093524A2 Method for preparing amorphous precipitated protein particles |
| 06/27/2013 | WO2013093465A2 Novel formulations |
| 06/27/2013 | WO2013093456A1 Drug delivery technology |
| 06/27/2013 | WO2013093216A1 Topical film-forming composition, and use thereof for treating or preventing onychophagia |
| 06/27/2013 | WO2013092998A1 Enzymatic conjugation of antibodies |
| 06/27/2013 | WO2013092983A2 Enzymatic conjugation of polypeptides |
| 06/27/2013 | WO2013092786A1 Compositions comprising cetilistat |
| 06/27/2013 | WO2013092673A2 New combination |
| 06/27/2013 | WO2013092497A1 Immediate release multi unit pellet system |
| 06/27/2013 | WO2013091283A1 Pharmaceutical compositions of triptorelin microspheres |
| 06/27/2013 | WO2013091001A1 A peptide-hydrogel composite |
| 06/27/2013 | WO2013056108A3 Solid dispersions of a erb2 (her2) inhibitor |
| 06/27/2013 | WO2013021346A3 A novel method for peroral delivery of insulin and its analogues for therapeutic usage |
| 06/27/2013 | US20130165970 Bonding tissues and cross-linking proteins wth naphthalimide compounds |
| 06/27/2013 | US20130165880 Antimicrobial disposable absorbent articles |
| 06/27/2013 | US20130165628 Double Binding Constructs |
| 06/27/2013 | US20130165624 Selective Binding Compounds |
| 06/27/2013 | US20130165503 Method for Treating Ocular Neovascularization |
| 06/27/2013 | US20130165466 Polymer conjugates of opioid antagonists |
| 06/27/2013 | US20130165405 Cyclodextrin-based polymers for therapeutics delivery |
| 06/27/2013 | US20130165381 Lipids, lipid complexes and use thereof |
| 06/27/2013 | US20130165378 Method of treating human growth hormone mediated condition |
| 06/27/2013 | US20130165377 Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
| 06/27/2013 | US20130164843 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164815 Process for the production of a reversibly inactive acidified plasmin composition |
| 06/27/2013 | US20130164377 Shell-and-core dosage form approaching zero-order drug release |
| 06/27/2013 | US20130164374 Reduction in bacterial colonization by administering bacteriophage compositions |
| 06/27/2013 | US20130164368 Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
| 06/27/2013 | US20130164366 Method and medicament for inhibiting the expression of a given gene |
| 06/27/2013 | US20130164346 Method for preparing biomedical metal alloy material with multi-drug delivery system |
| 06/27/2013 | US20130164341 Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 06/27/2013 | US20130164335 Methods and compositions for cellular drug release |
| 06/27/2013 | US20130164311 Composition, preparation, and use of dense chitosan membrane materials |
| 06/27/2013 | US20130164309 Antibodies to the b12-transcobalamin receptor |
| 06/27/2013 | US20130164296 Excipients for Stabilising Viral Particles, Polypeptides or Biological Material |
| 06/27/2013 | US20130164282 Treatment of cancer |
| 06/27/2013 | US20130164273 Reversibly inactivated acidified plasmin composition |
| 06/27/2013 | US20130164256 Immunobinders directed against tnf |
| 06/27/2013 | US20130164250 Method for production of bioresorbable microparticles, microparticles thus obtained and use thereof |
| 06/27/2013 | US20130164227 Production method and effervescent formulations comprising cephalosporin and clavulanic acid |
| 06/27/2013 | US20130164216 Bladder cancer tumor marker, antibody and use thereof |
| 06/27/2013 | US20130164214 Antibody-Based Depletion of Antigen-Presenting Cells and Dendritic Cells |
| 06/27/2013 | US20130161228 Containers for compositions comprising meloxicam |
| 06/27/2013 | US20130160761 Pharmaceutical Aerosol Composition |
| 06/26/2013 | EP2606911A1 Receptor And Antigen Targeted Prodrug |
| 06/26/2013 | EP2606910A1 Pharmaceutical composition for transcolonic absorption |
| 06/26/2013 | EP2606899A1 High viscosity macromolecluar compositions for treating ocular conditions |
| 06/26/2013 | EP2606886A1 Composition containing tetracyclic compound |
| 06/26/2013 | EP2606881A1 Fat-reducing agent |
| 06/26/2013 | EP2606877A1 Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules |
| 06/26/2013 | EP2606865A1 Compositions for transdermal oxybutynin therapy |
| 06/26/2013 | EP2605803A1 Method of stabilizing and sterilizing peptides or proteins |
| 06/26/2013 | EP2605797A2 Therapeutic peptide-polymer conjugates, particles, compositions, and related methods |
| 06/26/2013 | EP2605796A1 Engineering multifunctional and multivalent molecules with collagen xv trimerization domain |
| 06/26/2013 | EP2605795A2 Intravaginal devices, methods of making, and uses thereof |
| 06/26/2013 | EP2605794A1 Oligonucleotide chelate complexes |
| 06/26/2013 | EP2605788A2 Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases |
| 06/26/2013 | EP2605757A2 Nalbuphine-based formulations and uses thereof |
| 06/26/2013 | EP2605756A2 Functional food compositions and methods |
| 06/26/2013 | EP2605755A1 Particulate substances comprising ceramic particles for delivery of biomolecules |
| 06/26/2013 | EP2605753A2 Topical gel composition |
| 06/26/2013 | EP2605752A1 Ophthalmic formulations of squalamine |
| 06/26/2013 | EP2605746A2 Filler composition comprising beta-glucans |
| 06/26/2013 | CN1913876B Drug-containing grains and solid preparation containing the grains |
| 06/26/2013 | CN103180333A Glycodendrimers of polypropyletherimine |
| 06/26/2013 | CN103179988A Pharmaceutical composition for transcolonic absorption |
| 06/26/2013 | CN103179972A Use of storage stable viscous phospholipid depot to treat wounds |